

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Proposal for resolution on (A) amendment of the Articles of Association; and (B) reverse share split

The board of directors of Immunovia AB (publ), Reg. No. 556730-4299, proposes that the Extraordinary General Meeting on 22 January 2026 ("EGM") resolves on a consolidation of shares (so-called reverse share split) whereby hundred (100) existing shares are consolidated into one (1) share (1:100) in accordance with B below. The purpose of the reverse share split is to achieve an appropriate number of shares for the company. In order to enable the reverse share split, the board of directors further proposes that the EGM resolves to amend the company's Articles of Association in accordance with A below.

A. Amendment of the Articles of Association

In order to enable the reverse share split proposed under B below, the board of directors proposes that the EGM resolves to amend the company's Articles of Association, by adopting new limits for the share capital and the number of shares as follows.

§ 4 Share capital

Current wording

The share capital shall be not less than SEK 9,000,000 and not more than SEK 36,000,000.

Proposed wording

The share capital shall be not less than SEK 19,500,000 and not more than SEK 78,000,000.

§ 5 Number of shares

Current wording

The number of shares shall be not less than 300,000,000 and not more than 1,200,000,000.

Proposed wording

The number of shares shall be not less than 6,500,000 and not more than 26,000,000.

B. Reverse share split

The board of directors proposes that the EGM resolves to carry out a reverse share split, in the ratio 1:100, resulting in hundred (100) shares being consolidated into one (1) share.

The reason for the reverse share split is that the company wants to achieve a number of shares that is appropriate for the company.

If a shareholder's holding of shares does not correspond to a full number of new shares, the excess shares will become the property of the company on the record date for the reverse share split. Excess shares will then be sold at the company's expense by Vator Securities AB, whereby the shareholders concerned will receive their share of the sales proceeds.

After completion of the reverse share split, the number of shares in the company will decrease from 672,666,892 to 6,726,668 (rounded downwards). The proposed reverse share split also means that the quota value of the share increases from SEK 0.03 to approximately SEK 3.00.

The board of directors shall be authorized to determine the record date for the reverse share split, which may not, however, be earlier than the date on which the resolution on the reverse share split has been registered with the Swedish Companies Registration Office. Further information on the procedure for the reverse share split will be published in connection with the board of directors' resolution regarding the record date.

The board of directors' proposals under A – B above constitute a combined proposal and shall be made as a joint resolution.

For a valid resolution, the proposal has to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the EGM.

The company's CEO shall be authorized to make minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

Lund in December 2025

The Board of Directors of Immunovia AB (publ)